Research scientist working among genomic sequencing instruments in a biotech laboratory

Healthcare Public Relations

Biotech PR for Science That Is Not Finished Yet

Communications for biotech and life sciences companies — building a credible public narrative around science that is still in progress, without overpromising the outcome.

1997
Founded
29 Yrs
In Public Relations
US-Based
Senior Team
Award-Winning
PR Agency

Why Choose AMW for Biotech PR

Biotech communications have a structural tension: the most interesting thing about your company may be years from proving out. You need investors, partners, and talent to believe in the science now, while being scrupulously accurate about what has and has not been demonstrated. Overstate it and you lose the scientific audience permanently. Understate it and you struggle to raise.

We work with biotech and life sciences companies to hold that line — building narratives that convey genuine scientific promise while being precise about stage, evidence, and uncertainty. In practice that means leading with mechanism and rationale rather than implied outcomes, and being explicit about what a given milestone does and does not establish.

From seed and Series A visibility through trial milestones, publications, partnerships, and platform expansion, we scope the programme to your stage. Biotech PR sits inside our wider healthcare PR practice and connects closely to our investor relations work.

Challenges

  • Communicating scientific promise honestly when the outcome is genuinely not yet known
  • Reaching investor and partner audiences without alienating scientific peers
  • Explaining a novel mechanism or platform to journalists without a science background
  • Building visibility during long, quiet development periods between readouts
  • Competing for attention against companies willing to overstate their position
  • Coordinating communications around publications, trial milestones, and financing events

Our Solutions

  • Stage-accurate narratives that convey promise without implying results you do not have
  • Mechanism-led storytelling that scientific audiences respect and generalists can follow
  • Targeted outreach across life sciences trade, business, and investor-facing media
  • Founder and chief scientific officer positioning as credible voices on the science
  • Milestone communications planned around readouts, publications, and financing
  • Sustained visibility programs for the long quiet stretches between events

Ready to make a move on your biotech pr?

Get a tailored plan and pricing — no obligation, just a clear next step.

Get a Free Quote

Why Work With AMW

A public narrative that supports fundraising without damaging scientific credibility
Recognition among the partners and investors who evaluate your category
Scientific leadership positioned as expert voices, not just company representatives
Consistent presence through development periods rather than silence between raises

Our Process

A proven approach to delivering exceptional biotech pr results

1

Science and Stage Assessment

We work through your platform, pipeline, and evidence to establish what can be claimed at your current stage and where the language must stay careful.

2

Narrative Development

We build the mechanism-led story that works for scientific peers, investors, and business press, with clear boundaries around what each milestone demonstrates.

3

Milestone-Aligned Outreach

Media and commentary programs sequenced around publications, trial milestones, partnerships, and financing events.

4

Reporting and Adjustment

Monthly reporting on coverage, message accuracy, and audience reception, with the narrative refined as the science progresses.

Who We Work With

Our biotech pr expertise serves a wide range of clients

Clinical and preclinical stage biotech companies Life sciences platform and research tools companies Therapeutics developers approaching trial milestones Biotech founders and chief scientific officers Companies announcing financing rounds or pharma partnerships Life sciences investors and their portfolio companies
Verified Review
"I love working with AMW, they are extremely professional & immensely helpful in helping to spread your work throughout the digital landscape we all are in today. Christine has been a huge help to me & I hope if you read this review that you get to work with her team !Looking forward to even more growth & great work from them !"
IvoryMusic
Verified Review

Related Content

Frequently Asked Questions

What does a biotech PR agency do?
A biotech PR agency builds the public narrative around science that is still developing — communicating mechanism, platform, and milestones to investors, partners, scientific peers, and press. The work spans narrative development, trial and publication communications, financing and partnership announcements, and positioning your scientific leadership as credible expert voices.
When should a biotech company start PR?
Usually earlier than the first major readout. Investors, partners, and future hires form views over time, and companies that appear only at financing events are introducing themselves at the exact moment they need to be already known. Early work is narrative development and founder visibility rather than product announcements.
How do you communicate promise without overstating results?
By leading with mechanism and rationale rather than implied outcomes, and being explicit about stage. A preclinical result is described as a preclinical result. This is not just an ethical position — scientific and investor audiences read carefully, and a company that overstates once is discounted afterward. Precision is a credibility asset in this category.
How much does biotech PR cost?
Biotech communications are typically retained monthly, with cost driven by stage, milestone density, and whether you need continuous visibility or event-driven support. Early-stage programs are usually lighter than launch or late-clinical support. We scope against your pipeline and milestones rather than quoting a generic range.
Can you support us around a publication or conference?
Yes. Peer-reviewed publications and major conference presentations are among the most credible moments a biotech has, and they are frequently underused. We coordinate the public communications around them so the scientific milestone also produces business visibility.
What do we do during long quiet development periods?
This is where most biotech communications fail. Between milestones we build programs around category and mechanism commentary, scientific leadership visibility, and contribution to the broader industry conversation. It keeps you present with investors and partners during the stretches when there is no formal news.

Ready to Elevate Your Biotech PR?

Let's discuss how our specialized biotech pr expertise can drive results for your brand. Tailored strategy for your goals.